Wave Life Sciences Ltd. — Major Shareholding Notification 2023

Feb 10, 2023

SC 13G/A 1 p23-0786sc13ga.htm WAVE LIFE SCIENCES LTD.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13G/A
Under the Securities Exchange Act of 1934
(Amendment No. 1)*
Wave Life Sciences
Ltd.
(Name of Issuer)
Ordinary Shares,
no par value
(Title of Class of Securities)
Y95308105
(CUSIP Number)
December 31, 2022
(Date of Event Which Requires Filing of this Statement)
Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
¨	Rule 13d-1(b)
x	Rule 13d-1(c)
¨	Rule 13d-1(d)
(Page 1 of 6 Pages)

---

• The remainder of this cover page shall be filled out for a reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

The information required in the remainder of this cover page shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934 (the "Act") or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

Field: Page; Sequence: 1; Options: NewSection; Value: 2

CUSIP No. Y95308105 13G/A Page 2 of 6 Pages

Field: /Page

1	NAMES OF REPORTING PERSONS M28 Capital Management LP
2	CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP	(a) ¨ (b) ¨
3	SEC USE ONLY
4	CITIZENSHIP OR PLACE OF ORGANIZATION Delaware
NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:	5	SOLE VOTING POWER - 0 -
	6	SHARED VOTING POWER 5,903,405
	7	SOLE DISPOSITIVE POWER - 0 -
	8	SHARED DISPOSITIVE POWER 5,903,405
9	AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON 5,903,405
10	CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES	¨
11	PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9) 6.8%
12	TYPE OF REPORTING PERSON PN, IA

Field: Page; Sequence: 2; Value: 2

CUSIP No. Y95308105 13G/A Page 3 of 6 Pages

Field: /Page

Item 1(a).
The name of the issuer is Wave Life Sciences Ltd. (the " Company ").

Item 1(b).
The Company's principal executive offices are located at 7 Straits View #12-00, Marina One East Tower, Singapore 018936.

Item 2(a).
This statement is filed by M28 Capital Management LP (the " Firm " or the " Reporting Person ").

Item 2(b).
The address for the Firm is 700 Canal Street, 2nd Floor, Stamford, CT 06902.

Item 2(c).
The Firm is a Delaware limited partnership.

Item 2(d).
Ordinary shares, no par value (the " Ordinary Shares ").

Item 2(e).
Y95308105

ITEM 3. IF THIS STATEMENT IS FILED PURSUANT TO §§ 240.13d-1(b) OR 240.13d-2(b) OR (c), CHECK WHETHER THE PERSON FILING IS A:

(a)	¨	Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
(b)	¨	Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	¨	Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	¨	Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	¨	Investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E);

Field: Page; Sequence: 3; Value: 2

CUSIP No. Y95308105 13G/A Page 4 of 6 Pages

Field: /Page

| (f) | ¨ | Employee benefit plan or endowment fund in accordance
with Rule 13d-1(b)(1)(ii)(F); |
| --- | --- | --- |
| (g) | ¨ | Parent holding company or control person in accordance
with Rule 13d-1(b)(1)(ii)(G); |
| (h) | ¨ | Savings association as defined in Section 3(b) of the Federal Deposit Insurance
Act (12 U.S.C. 1813); |
| (i) | ¨ | Church plan that is excluded from the definition of an investment company
under Section 3(c)(14) of the Investment Company Act (15 U.S.C. 80a-3); |
| (j) | ¨ | Non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); |
| (k) | ¨ | Group, in accordance with Rule 13d-1(b)(1)(ii)(K). |

If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please
specify the type of institution:

Item 4.
The information required by Items 4(a) - (c) is set forth in Rows 5 - 11 of
the cover page for the Reporting Person hereto and is incorporated herein by reference for the Reporting Person.
The percentages used in this Schedule 13G/A are calculated based upon 86,900,688 Ordinary Shares outstanding as of November 1, 2022, as reported in the Issuer's Quarterly Report on Form 10-Q for the quarter ending September 30, 2022 filed with the Securities and Exchange Commission on November 10, 2022.

Item 5.
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following: o .

Item 6.
Not applicable.

Field: Page; Sequence: 4; Value: 2

CUSIP No. Y95308105 13G/A Page 5 of 6 Pages

Field: /Page

Item 7.
Not applicable.

Item 8.
Not applicable.

Item 9.
Not applicable.

Item 10.
The Reporting Persons hereby makes the following certification:
By signing below, the Reporting Person certifies that, to the best of his or its knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Field: Page; Sequence: 5; Value: 2

CUSIP No. Y95308105 13G/A Page 6 of 6 Pages

Field: /Page

SIGNATURES

After reasonable inquiry and to the best of our knowledge and belief, the undersigned certify that the information set forth in this statement is true, complete and correct.

DATED: February 10, 2023

M28 Capital Management LP
/s/ Christopher M. Taliercio
Christopher M. Taliercio, President and Chief Compliance Officer